Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Beyond The Numbers: 25 Analysts Discuss Eli Lilly Stock
Via Benzinga
Eli Lilly: A Pharmaceutical Juggernaut That Just Crushed Earnings Estimates
Many have said that pharmaceutical companies would be a logical place to invest if the rest of the market began to slow down. They may have been onto something. Eli Lilly & Co. reported Q2 earnings and... 
Via Talk Markets
A Blood Test Could Detect Early Alzheimer's. That Could Make These 2 Stocks Red-Hot Buys.
These companies have approved Alzheimer's treatments that could generate billions in revenue for their respective businesses. 
Via The Motley Fool
MarketBeat Week in Review – 8/5 - 8/9
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Analyzing Eli Lilly In Comparison To Competitors In Pharmaceuticals Industry
Via Benzinga
Eli Lilly Unusual Options Activity
Via Benzinga
Why Eli Lilly Stock Just Jumped 8%
How fast must Lilly grow to justify a 54.5 P/E ratio? 
Via The Motley Fool
3 Stocks to Load-Up On Before Autumn Arrives
Consider these stocks to buy before autumn as each has delivered strong financial results and seen their share price rise as a result. 
Via InvestorPlace
Lilly Stock Surging On Healthy Profits: Check Out Who's On The IBD 50, Other Premium Lists
Lilly last week reported an 86% surge in earnings to $3.92 a share, easily beating estimates, as revenue popped 35% to $11.3 billion. 
Via Investor's Business Daily
S&P 500 Erases Weekly Losses, Nasdaq 100 Ends 4-Week Slide As Bulls Regain Momentum: Friday's Stock Movers At The Close
Market indexes rose on Friday, wiping out weekly losses and easing economic fears. Positive catalysts calmed volatility and reassured investors. 
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
Eli Lilly's Q2 revenue soared to $11.3 billion, surpassing forecasts. Mounjaro sales tripled and Zepbound revenue grew significantly post-FDA approval. Analysts are cautious about future supply and... 
Via Benzinga
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday?
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic... 
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
3 Healthcare Stocks to Sell in August Before They Crash & Burn
Investors are looking to the healthcare sector for safe harbor. But these are three healthcare stocks to sell in August 2024. 
Via InvestorPlace
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide. 
Via MarketBeat
Topics ETFs
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space. 
Via The Motley Fool
Eli Lilly & Co. Stocks Elliott Wave Technical Analysis - Friday, August 9
Looking for a top in wave {b} of 4 to then complete the overall correction, knowing we could already have a bottom in Minor wave 4 in place. 
Via Talk Markets
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in. 
Via MarketBeat
2 Healthcare Stocks to Buy Hand Over Fist in August
These longtime winners still have a lot to offer. 
Via The Motley Fool
S&P 500 Records Best Session Since January 2023: Investor Sentiment Improves, But Greed Index Remains In 'Extreme Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Eli Lilly Shatters Q2 Estimates, Boosts Annual Guidance on Mounjaro and Zepbound Surge
Eli Lilly Shatters Q2 Estimates, Boosts Annual Guidance on Mounjaro and Zepbound Surge 
Via Chartmill
Eli Lilly (LLY) Q2 2024 Earnings Call Transcript
LLY earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Dow Jumps Over 500 Points; Eli Lilly Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Eli Lilly And Company Shines In Q2 With $11.30B Revenue, 68% EPS Growth
Eli Lilly and Company has reported a strong financial performance for the second quarter of 2024, with revenue reaching $11.30 billion. 
Via Talk Markets
LLY Stock Alert: Why Are Eli Lilly Shares Surging Today?
Eli Lilly's growth should accelerate now that shortages of its GLP-1 drugs are resolved, but competitors are coming. 
Via InvestorPlace
Mounjaro Maker Eli Lilly's Bumper Q2 Earnings Exceeds Estimates, Hikes Outlook Again On Strong Diabetes And Weight Loss Drugs Sales
Eli Lilly's Q2 revenue surged 36% year-over-year to $11.3 billion, driven by strong sales of Mounjaro, Zepbound, and other key drugs. The company raised its 2024 sales and EPS guidance, citing improved... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.